Phase 2 N=48 Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)
Pneumonia Due to Staphylococcus Aureus
Primary: Efficacy Endpoint: All-Cause Mortality by Day 28 — 1; 2; 2; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=52 Early Sodium Intake in Preterm Newborns
Hyponatremia · Premature
Primary: Hyponatremia — 6; 1 Participants — p=0.71
N/A N=253 Reducing the Burden of Depression Related Disability
Depression
Primary: Improvement in Work Related Disability Post Intervention — -2.1; -0.09 units on a scale
N/A N=60 Endostapler Hemostasis Study
Intraoperative Staple Line Bleeding as Measured by the Provided Bleeding Severity Scale
Primary: Staple Line Bleeding — 2.08; 2.57 score on a scale — p=0.01
Phase 3 N=382 A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
Hyperlipidemias
Primary: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) — -36.2; -17.2; -23.2; 1.8 Percent Change — p=<0.001
Phase 2 N=47 Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus
Primary: Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12 — -4.5; -8.7; -5.5 score on a scale — p=0.7500
N/A N=181 Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
Benign Prostatic Hyperplasia (BPH)
Primary: Proportion of Subjects With Adverse Events (Clavien-Dindo Grading System Grade 2 or Higher or Any Grade 1 Event Resulting in Persistent Disability) — 26; 42 percentage…
N/A N=43 Adjunctive Nitrous Oxide During Emergency Department Propofol Sedation in Adults
Joint Dislocation · Perianal Abscess · Abscess
Primary: Total Number of Respiratory Depression Events — 0 events
N/A N=108 Mechanisms of Antidepressant Non-Response in Late-Life Depression
Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HRSD) — 22.8; 23.6; 22.9 units on a scale
Phase 3 N=391 A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
Rheumatoid Arthritis
Primary: Area Under the Concentration-time Curve (AUCτ) of Infliximab at Steady State (Part 1) — 12032957.5; 5047724.2; 7333767.0; 9930696.6 hr*ng/mL
N/A N=15 Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: High Blood Glucose Index (HBGI) — 6.87; 8.05; 7.92; 9.00 index score — p=0.023
N/A N=144 Naltrexone for Antipsychotic-Induced Weight Gain
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Weight From Baseline — -0.16; 0.69; -0.95 kg — p=0.83
N/A N=23,357 A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Difference in Mean CKD Register Patient eGFRs Between Groups After 3.5 Years of Study — -2.00; -2.29 mean average eGFR change/mL/min/1.73 m^2
Phase 2 N=20 Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women
Alopecia
Primary: Change in Hair Count — 7.7; 22.7 percent change — p=.009
Phase 3 N=2,101 Actual Use Study of Tamsulosin in Men
Urological Manifestations
Primary: Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product and do Not…